Bone Cancer

P3, N=123, Active, not recruiting, Deciphera Pharmaceuticals, LLC | Trial completion date: Jul 2026 --> Jul 2028

P=N/A, N=72, Recruiting, Mayo Clinic | Trial completion date: Aug 2028 --> Aug 2031

The remaining patients were alive and well at 16 to 33 months. MPC represents a distinct clinicopathological entity with frequent c-MYC amplification and may benefit from targeted MYC inhibition.

Proteomic analysis revealed that NCC-GCTB16-C1 exhibited properties similar to those of the original tumor tissue. Thus, NCC-GCTB16-C1 provides an in vitro model that faithfully reflects the molecular and phenotypic features of GCTB, offering a valuable tool for mechanistic studies and preclinical drug evaluation.

The immunosuppressive chordoma TME is associated with clinical outcomes and our data suggests OV infection reverses this deleterious immunosuppressive profile. These studies provide a framework for future clinical implementation amongst chordoma patients.

Percentage of spindled pattern and primary tumor diameter are potential prognostic factors for recurrence and metastasis, respectively, in GCTB.

CSF1R inhibitor can inhibit the tumor growth of recurrent GCTB. Targeting CSF1R and alleviating T cell exhaustion may provide therapeutic insights for the management of relapsed GCTB following DMAb discontinuation.

In this study, we demonstrated that thyroid cancer is the most common malignancy in Turkish acromegalic patients, consistent with the results of previous studies. The increased cancer risk in acromegalic patients did not correlate with age, sex, age at diagnosis, time to diagnosing acromegaly, duration of acromegaly, or GH and IGF-1 levels at diagnosis.

The targeted inhibition of osteoclast activity with denosumab has transformed clinical management, inducing profound morphological changes and bone formation...Collectively, GCTB exemplifies a molecularly defined bone tumor in which advances in epigenetic biology and tumor-microenvironment interactions have directly influenced diagnostic practice and therapeutic strategy. Ongoing challenges include refining risk stratification, optimizing treatment sequencing, and clarifying the biological consequences of sustained osteoclast suppression.

These findings suggest the potential role of CHI3L1 in chordoma tumorigenesis, emphasizing its relevance as a biomarker and therapeutic target for primary tumors. Future studies are necessary to elucidate the mechanistic role of CHI3L1 in chordoma immune evasion and to explore targeted interventions that may improve patient outcomes in this aggressive cancer.

He underwent an extensive en bloc resection of the tumour. We also discuss the signs, symptoms, relevant investigations, and various treatment options in managing a patient with pleomorphic RMS.

P2, N=29, Active, not recruiting, M.D. Anderson Cancer Center | N=15 --> 29 | Recruiting --> Active, not recruiting